<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"> <head> <meta http-equiv=Content-Type content="text/html; charset=unicode"> <meta name=ProgId content=Word.Document> <meta name=Generator content="Microsoft Word 14"> <meta name=Originator content="Microsoft Word 14"> <link rel=File-List href="Thoracic%20_files/filelist.xml"> <link rel=Edit-Time-Data href="Thoracic%20_files/editdata.mso"> <!--[if !mso]> <style> v\:* {behavior:url(#default#VML);} o\:* {behavior:url(#default#VML);} w\:* {behavior:url(#default#VML);} .shape {behavior:url(#default#VML);} </style> <![endif]--> <link rel=themeData href="Thoracic%20_files/themedata.thmx"> <link rel=colorSchemeMapping href="Thoracic%20_files/colorschememapping.xml"> <!--[if gte mso 9]><xml> <w:WordDocument> <w:Zoom>0</w:Zoom> <w:TrackMoves/> <w:TrackFormatting/> <w:ValidateAgainstSchemas/> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <w:DoNotPromoteQF/> <w:LidThemeOther>EN-US</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript> <w:Compatibility> <w:DoNotExpandShiftReturn/> <w:BreakWrappedTables/> <w:SplitPgBreakAndParaMark/> <w:EnableOpenTypeKerning/> </w:Compatibility> <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel> <m:mathPr> <m:mathFont m:val="Cambria Math"/> <m:brkBin m:val="before"/> <m:brkBinSub m:val="&#45;-"/> <m:smallFrac m:val="off"/> <m:dispDef/> <m:lMargin m:val="0"/> <m:rMargin m:val="0"/> <m:defJc m:val="centerGroup"/> <m:wrapIndent m:val="1440"/> <m:intLim m:val="subSup"/> <m:naryLim m:val="undOvr"/> </m:mathPr></w:WordDocument> </xml><![endif]--><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true" DefSemiHidden="true" DefQFormat="false" DefPriority="99" LatentStyleCount="267"> <w:LsdException Locked="false" Priority="0" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" Priority="39" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" Name="toc 9"/> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/> <w:LsdException Locked="false" Priority="10" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Title"/> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/> <w:LsdException Locked="false" Priority="11" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" Priority="22" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" Priority="59" SemiHidden="false" UnhideWhenUsed="false" Name="Table Grid"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/> <w:LsdException Locked="false" Priority="34" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles> </xml><![endif]--> <style> <!-- /* Font Definitions */ @font-face {font-family:Wingdings; panose-1:5 0 0 0 0 0 0 0 0 0; mso-font-charset:2; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:0 268435456 0 0 -2147483648 0;} @font-face {font-family:Wingdings; panose-1:5 0 0 0 0 0 0 0 0 0; mso-font-charset:2; mso-generic-font-family:auto; mso-font-pitch:variable; mso-font-signature:0 268435456 0 0 -2147483648 0;} @font-face {font-family:Cambria; panose-1:2 4 5 3 5 4 6 3 2 4; mso-font-charset:0; mso-generic-font-family:roman; mso-font-pitch:variable; mso-font-signature:-536870145 1073743103 0 0 415 0;} @font-face {font-family:Calibri; panose-1:2 15 5 2 2 2 4 3 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-536870145 1073786111 1 0 415 0;} @font-face {font-family:Verdana; panose-1:2 11 6 4 3 5 4 4 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:-1593833729 1073750107 16 0 415 0;} @font-face {font-family:"Trebuchet MS"; panose-1:2 11 6 3 2 2 2 2 2 4; mso-font-charset:0; mso-generic-font-family:swiss; mso-font-pitch:variable; mso-font-signature:647 0 0 0 159 0;} /* Style Definitions */ p.MsoNormal, li.MsoNormal, div.MsoNormal {mso-style-unhide:no; mso-style-qformat:yes; mso-style-parent:""; margin:0in; margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman","serif"; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin;} h1 {mso-style-priority:9; mso-style-unhide:no; mso-style-qformat:yes; mso-style-link:"Heading 1 Char"; mso-margin-top-alt:auto; margin-right:0in; mso-margin-bottom-alt:auto; margin-left:0in; mso-pagination:widow-orphan; mso-outline-level:1; font-size:24.0pt; font-family:"Times New Roman","serif"; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin; font-weight:bold;} a:link, span.MsoHyperlink {mso-style-noshow:yes; mso-style-priority:99; color:blue; text-decoration:underline; text-underline:single;} a:visited, span.MsoHyperlinkFollowed {mso-style-noshow:yes; mso-style-priority:99; color:purple; text-decoration:underline; text-underline:single;} p {mso-style-priority:99; mso-margin-top-alt:auto; margin-right:0in; mso-margin-bottom-alt:auto; margin-left:0in; mso-pagination:widow-orphan; font-size:12.0pt; font-family:"Times New Roman","serif"; mso-fareast-font-family:Calibri; mso-fareast-theme-font:minor-latin;} span.Heading1Char {mso-style-name:"Heading 1 Char"; mso-style-priority:9; mso-style-unhide:no; mso-style-locked:yes; mso-style-link:"Heading 1"; font-family:"Cambria","serif"; mso-ascii-font-family:Cambria; mso-hansi-font-family:Cambria; color:#365F91; font-weight:bold;} span.EmailStyle19 {mso-style-type:personal; mso-style-noshow:yes; mso-style-unhide:no; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-hansi-font-family:Calibri; color:#1F497D;} .MsoChpDefault {mso-style-type:export-only; mso-default-props:yes; font-size:10.0pt; mso-ansi-font-size:10.0pt; mso-bidi-font-size:10.0pt;} @page WordSection1 {size:8.5in 11.0in; margin:1.0in 1.0in 1.0in 1.0in; mso-header-margin:.5in; mso-footer-margin:.5in; mso-paper-source:0;} div.WordSection1 {page:WordSection1;} /* List Definitions */ @list l0 {mso-list-id:2041544523; mso-list-template-ids:1812761806;} @list l0:level1 {mso-level-number-format:bullet; mso-level-text:; mso-level-tab-stop:.5in; mso-level-number-position:left; text-indent:-.25in; mso-ansi-font-size:10.0pt; font-family:Symbol;} @list l0:level2 {mso-level-number-format:bullet; mso-level-text:o; mso-level-tab-stop:1.0in; mso-level-number-position:left; text-indent:-.25in; mso-ansi-font-size:10.0pt; font-family:"Courier New"; mso-bidi-font-family:"Times New Roman";} @list l0:level3 {mso-level-number-format:bullet; mso-level-text:; mso-level-tab-stop:1.5in; mso-level-number-position:left; text-indent:-.25in; mso-ansi-font-size:10.0pt; font-family:Wingdings;} @list l0:level4 {mso-level-number-format:bullet; mso-level-text:; mso-level-tab-stop:2.0in; mso-level-number-position:left; text-indent:-.25in; mso-ansi-font-size:10.0pt; font-family:Wingdings;} @list l0:level5 {mso-level-number-format:bullet; mso-level-text:; mso-level-tab-stop:2.5in; mso-level-number-position:left; text-indent:-.25in; mso-ansi-font-size:10.0pt; font-family:Wingdings;} @list l0:level6 {mso-level-number-format:bullet; mso-level-text:; mso-level-tab-stop:3.0in; mso-level-number-position:left; text-indent:-.25in; mso-ansi-font-size:10.0pt; font-family:Wingdings;} @list l0:level7 {mso-level-number-format:bullet; mso-level-text:; mso-level-tab-stop:3.5in; mso-level-number-position:left; text-indent:-.25in; mso-ansi-font-size:10.0pt; font-family:Wingdings;} @list l0:level8 {mso-level-number-format:bullet; mso-level-text:; mso-level-tab-stop:4.0in; mso-level-number-position:left; text-indent:-.25in; mso-ansi-font-size:10.0pt; font-family:Wingdings;} @list l0:level9 {mso-level-number-format:bullet; mso-level-text:; mso-level-tab-stop:4.5in; mso-level-number-position:left; text-indent:-.25in; mso-ansi-font-size:10.0pt; font-family:Wingdings;} ol {margin-bottom:0in;} ul {margin-bottom:0in;} --> </style> <!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin:0in; mso-para-margin-bottom:.0001pt; mso-pagination:widow-orphan; font-size:10.0pt; font-family:"Times New Roman","serif";} </style> <![endif]--><!--[if gte mso 9]><xml> <o:shapedefaults v:ext="edit" spidmax="1029"/> </xml><![endif]--><!--[if gte mso 9]><xml> <o:shapelayout v:ext="edit"> <o:idmap v:ext="edit" data="1"/> </o:shapelayout></xml><![endif]--> </head> <body lang=EN-US link=blue vlink=purple style='tab-interval:.5in'> <div class=WordSection1> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;mso-cellspacing:0in;mso-yfti-tbllook:1184;mso-padding-alt: 0in 0in 0in 0in'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes'> <td style='padding:0in 0in 0in 0in'> <div align=center> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:6.25in;mso-cellspacing:0in;mso-yfti-tbllook:1184;mso-padding-alt: 0in 0in 0in 0in'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes'> <td style='padding:0in 0in 0in 0in'> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width=600 style='width:6.25in;mso-cellspacing:0in;mso-yfti-tbllook:1184;mso-padding-alt: 0in 0in 0in 0in'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes'> <td style='background:#DDEAF2;padding:0in 0in 0in 0in'> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;mso-cellspacing:0in;mso-yfti-tbllook: 1184;mso-padding-alt:0in 0in 0in 0in'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes'> <td valign=top style='padding:7.5pt 7.5pt 7.5pt 7.5pt'> <div> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;mso-cellspacing:0in;mso-yfti-tbllook: 1184;mso-padding-alt:0in 0in 0in 0in'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow: yes'> <td style='padding:0in 0in 0in 0in'> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'><img width=580 id="_x0000_i1025" src="http://staticapp.icpsc.com/icp/loadimage.php/mogile/815859/4451f83903a49598dc178e1060dc9057/image/jpeg"><o:p></o:p></span></p> </td> </tr> </table> </div> </td> </tr> </table> </td> </tr> <tr style='mso-yfti-irow:1'> <td style='padding:0in 0in 0in 0in'> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;mso-cellspacing:0in;mso-yfti-tbllook: 1184;mso-padding-alt:0in 0in 0in 0in;word-wrap:break-word'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes'> <td width="50%" valign=top style='width:50.0%;background:#DDEAF2; padding:0in 0in 0in 0in'> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;mso-cellspacing:0in;mso-yfti-tbllook: 1184;mso-padding-alt:0in 0in 0in 0in'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow: yes'> <td valign=top style='padding:7.5pt 7.5pt 7.5pt 7.5pt'> <div> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;mso-cellspacing:0in;mso-yfti-tbllook: 1184;mso-padding-alt:0in 0in 0in 0in'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow: yes'> <td style='padding:0in 0in 0in 0in'> <p style='margin:0in;margin-bottom:.0001pt'><strong><span style='font-size:10.0pt;font-family:"Verdana","sans-serif"; color:black'>TCGA discovers potential therapeutic targets for lung squamous cell carcinoma</span></strong><span style='font-size:8.5pt; font-family:"Trebuchet MS","sans-serif";color:black'><o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>Researchers have identified potential therapeutic targets in lung squamous cell carcinoma, the second most common form of lung cancer. The study found a large number and variety of DNA alterations, many of which seem to be driving forces behind pathways that are important to the initiation and progression of lung cancer.<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'> With these findings, TCGA researchers have set the stage for the development, testing and implementation of advanced diagnostics and therapeutics for lung squamous cell carcinoma, said NIH Director Francis S. Collins, MD, PhD.  These findings also underscore the power and value of our nation s investment in The Cancer Genome Atlas. <o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'><a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Funclineberger.org%2Fnews%2Fpotential-targets-for-lung-cancer">Read more</a>.<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> </td> </tr> </table> </div> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;mso-cellspacing:0in;mso-yfti-tbllook: 1184;mso-padding-alt:0in 0in 0in 0in'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow: yes'> <td style='padding:0in 0in 0in 0in'> <h1><span style='font-size:10.0pt;font-family:"Verdana","sans-serif"; mso-fareast-font-family:"Times New Roman";color:black'>UNC study highlights diagnosis of lung cancer subtypes</span><span style='font-family:"Trebuchet MS","sans-serif";mso-fareast-font-family: "Times New Roman";color:black'><o:p></o:p></span></h1> <p style='margin:0in;margin-bottom:.0001pt'><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f"> <v:stroke joinstyle="miter"/> <v:formulas> <v:f eqn="if lineDrawn pixelLineWidth 0"/> <v:f eqn="sum @0 1 0"/> <v:f eqn="sum 0 0 @1"/> <v:f eqn="prod @2 1 2"/> <v:f eqn="prod @3 21600 pixelWidth"/> <v:f eqn="prod @3 21600 pixelHeight"/> <v:f eqn="sum @0 0 1"/> <v:f eqn="prod @6 1 2"/> <v:f eqn="prod @7 21600 pixelWidth"/> <v:f eqn="sum @8 21600 0"/> <v:f eqn="prod @7 21600 pixelHeight"/> <v:f eqn="sum @10 21600 0"/> </v:formulas> <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/> <o:lock v:ext="edit" aspectratio="t"/> </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t75" alt="" style='position:absolute;margin-left:0;margin-top:0;width:101.25pt; height:70.5pt;z-index:251658240;mso-wrap-distance-left:0; mso-wrap-distance-top:0;mso-wrap-distance-right:0; mso-wrap-distance-bottom:0;mso-position-horizontal:left; mso-position-horizontal-relative:text; mso-position-vertical-relative:line' o:allowoverlap="f"> <v:imagedata src="http://staticapp.icpsc.com/icp/loadimage.php/mogile/815859/fa2a4000856eb001b87713b3c4dd3f0f/image/jpeg"/> <w:wrap type="square"/> </v:shape><![endif]--><![if !vml]><img width=135 height=94 src="http://cancer.med.unc.edu/lcccnewsletter/go-hayes.jpg" align=left v:shapes="_x0000_s1026"><![endif]><span style='font-size:8.5pt;font-family:"Trebuchet MS","sans-serif"; color:black'>A UNC-led study performed the most extensive review ever of the diagnostic accuracy of classification of tumors of the lung using light microscopy, and identified both areas of concern as well as opportunities for future improvement in the vital process of lung cancer diagnosis. <o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'> This study is important because we need to know what factors make the specimen slide most useful to pathologists. Of course, in clinical practice, any diagnosis is based on much more information and consultation than just the pathology slide; however, having the most informed pathology data is a key component in the diagnostic process,&quot; said Juneko Grilley-Olson, MD, co-first author, along with Neil Hayes, MD, MPH, of the study. <a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Funclineberger.org%2Fnews%2Fdiagnosing-lung-cancer-subtypes">Read more</a>.<o:p></o:p></span></p> </td> </tr> </table> <div> <p class=MsoNormal><span style='font-size:8.5pt;font-family:"Trebuchet MS","sans-serif"; color:black;display:none;mso-hide:all'><o:p>&nbsp;</o:p></span></p> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;mso-cellspacing:0in;mso-yfti-tbllook: 1184;mso-padding-alt:0in 0in 0in 0in;word-wrap:break-word'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow: yes'> <td style='padding:0in 0in 0in 0in'> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><strong><span style='font-size:10.0pt;font-family:"Verdana","sans-serif"; color:black'>Weiss discusses lung cancer highlights of 2011</span></strong><span style='font-size:8.5pt;font-family:"Trebuchet MS","sans-serif"; color:black'><o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><!--[if gte vml 1]><v:shape id="_x0000_s1027" type="#_x0000_t75" alt="" style='position:absolute; margin-left:0;margin-top:0;width:59.25pt;height:72.75pt;z-index:251659264; mso-wrap-distance-left:0;mso-wrap-distance-top:0; mso-wrap-distance-right:0;mso-wrap-distance-bottom:0; mso-position-horizontal:left;mso-position-horizontal-relative:text; mso-position-vertical-relative:line' o:allowoverlap="f"> <v:imagedata src="http://staticapp.icpsc.com/icp/loadimage.php/mogile/815859/2a5ee819ff8fe2138cdca05eddc1755e/image/jpeg"/> <w:wrap type="square"/> </v:shape><![endif]--><![if !vml]><img width=79 height=97 src="http://cancer.med.unc.edu/lcccnewsletter/weiss.jpg" align=left v:shapes="_x0000_s1027"><![endif]><span style='font-size:8.5pt;font-family:"Trebuchet MS","sans-serif"; color:black'>In a three-part webinar, Jared Weiss, MD, talks about the EGFR axis (part 1), ALK and other new molecular targets (part 2) and CT screening and optimal management of elderly patients with advanced NSCLC (part 3). The webinar was produced by GRACE (Global Resource for Advancing Cancer Education) in partnership with the LUNGEVITY Foundation. <o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'><a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Fcancergrace.org%2Flung%2F2012%2F03%2F15%2F2011-highlights-in-lung-cancer-by-dr-jared-weiss-part-1-the-egfr-axis%2F">Listen to his comments</a>.<o:p></o:p></span></p> </td> </tr> </table> </div> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;mso-cellspacing:0in;mso-yfti-tbllook: 1184;mso-padding-alt:0in 0in 0in 0in'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow: yes'> <td style='padding:0in 0in 0in 0in'> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><strong><span style='font-size:10.0pt;font-family:"Verdana","sans-serif"; color:black'>Other Highlights</span></strong><span style='font-size:8.5pt;font-family:"Trebuchet MS","sans-serif"; color:black'><o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'><a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=https%3A%2F%2Fwww.unclineberger.org%2Fnews%2Flung-cancer-therapy">Molecular subtypes and genetic alterations may determine response to lung cancer therapy</a> <em><span style='font-family:"Trebuchet MS","sans-serif"'>A UNC-led team of scientists has shown for the first time that lung cancer molecular subtypes correlate with distinct genetic alterations and with patient response to therapy.</span></em><o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'><a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Fthoracicsymposium.org%2FMeetingProgram%2FAgenda.htm">Lawrence B. Marks, MD, FASTRO, keynote speaker at 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology</a><em><span style='font-family:"Trebuchet MS","sans-serif"'> The title of his talk was &quot;Evolution of Novel Radiation Strategies to Improve Therapeutic Index.&quot; </span></em><o:p></o:p></span></p> </td> </tr> </table> <p class=MsoNormal><span style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p> </td> </tr> </table> </td> <td width="50%" valign=top style='width:50.0%;background:#DDEAF2; padding:0in 0in 0in 0in;border:transparent'> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;mso-cellspacing:0in;mso-yfti-tbllook: 1184;mso-padding-alt:0in 0in 0in 0in;word-wrap:break-word'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow: yes'> <td valign=top style='padding:7.5pt 7.5pt 7.5pt 7.5pt;word-wrap:break-word'> <div> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;mso-cellspacing:0in;mso-yfti-tbllook: 1184;mso-padding-alt:0in 0in 0in 0in'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow: yes'> <td style='padding:0in 0in 0in 0in'> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'><span style='text-decoration:none;text-underline:none'><img src="http://cancer.med.unc.edu/lcccnewsletter/working-group.jpg" name="_x0000_i1026" width=280 height=168 border=0 id="_x0000_i1026"></span> <o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><em><span style='font-size:8.5pt;font-family:"Trebuchet MS","sans-serif"; color:black'>Participants in the The Cancer Genome Atlas Lung Squamous Cell Carcinoma Working Group: Face to Face Meeting at UNC</span></em><span style='font-size:8.5pt;font-family:"Trebuchet MS","sans-serif"; color:black'>. <a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Funclineberger.org%2Fnews%2Fpotential-targets-for-lung-cancer">Read more</a>.<o:p></o:p></span></p> </td> </tr> </table> </div> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;mso-cellspacing:0in;mso-yfti-tbllook: 1184;mso-padding-alt:0in 0in 0in 0in'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow: yes'> <td style='padding:0in 0in 0in 0in'> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><strong><span style='font-size:10.0pt;font-family:"Verdana","sans-serif"; color:black'>Current lung cancer clinical trials at UNC&nbsp; </span></strong><span style='font-size:8.5pt;font-family:"Trebuchet MS","sans-serif"; color:black'><o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'><a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Foncore.unc.edu%2Fsip%2FSIPControlServlet%3Fhdn_function%3DSIP_PROTOCOL_LISTINGS%26protocol_no%3DLCCC1123">LCCC1123</a>: Phase II Study Of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients with EGFR Mutation Who Have Previously Progressed on an EGFR-TKI. Affiliate sites include<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>the Leo W. Jenkins Cancer Center (East Carolina University), STO Taussig Cancer Center (Cleveland Clinic), the University of Pennsylvania, and the University of Pittsburgh Medical Center.<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'><a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Foncore.unc.edu%2Fsip%2FSIPControlServlet%3Fhdn_function%3DSIP_PROTOCOL_LISTINGS%26protocol_no%3DLCCC0921">LCCC0921</a>: A Multi-Center Open Label Phase II Study of Pazopanib In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer After Progression on First Line Therapy Containing Bevacizumab. Affiliate sites include Rex Healthcare and the University of Pittsburgh Medical Center.<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>LCCC1210: Phase II Study of weekly nab-paclitaxel for second line treatment of NSCLC in elderly patients<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'><a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Foncore.unc.edu%2Fsip%2FSIPControlServlet%3Fhdn_function%3DSIP_PROTOCOL_LISTINGS%26protocol_no%3DLCCC0825">LCCC0825</a>: A Multicenter Phase II Trial of Carboplatin, Pemetrexed, And Bevacizumab Followed By Pemetrexed And Bevacizumab Maintenance Therapy In Patients With A Light Or Never Smoking History AVF4499s. Affiliate sites include the New Bern Cancer Center, the University of Pittsburgh Medical Center, and Mission Cancer Center.<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'><a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Foncore.unc.edu%2Fsip%2FSIPControlServlet%3Fhdn_function%3DSIP_PROTOCOL_LISTINGS%26protocol_no%3DLCCC1030">LCCC1030</a>: A Phase Ib Study of Bavituximab plus Carboplatin and Pemetrexed in Chemotherapy-Nave Stage IV Non-Squamous Non-Small Cell Lung Cancer.<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>The University of Pittsburg Medical Center (UPMC) is an affiliate site for this clinical trial.<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'><a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Funclineberger.org%2Fthoracic%2Fclinical-trials-list">Read more about Thoracic Oncology Clinical Trials available at UNC</a>.<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> </td> </tr> </table> <div> <p class=MsoNormal><span style='font-size:8.5pt;font-family:"Trebuchet MS","sans-serif"; color:black;display:none;mso-hide:all'><o:p>&nbsp;</o:p></span></p> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;mso-cellspacing:0in;mso-yfti-tbllook: 1184;mso-padding-alt:0in 0in 0in 0in;word-wrap:break-word'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow: yes'> <td style='padding:0in 0in 0in 0in'> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><strong><span style='font-size:10.0pt;font-family:"Verdana","sans-serif"; color:black'>Wang receives grant from the Lung Cancer Research Foundation</span></strong><span style='font-size:8.5pt;font-family: "Trebuchet MS","sans-serif";color:black'><o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <div> <p style='margin:0in;margin-bottom:.0001pt'><!--[if gte vml 1]><v:shape id="_x0000_s1028" type="#_x0000_t75" alt="" style='position:absolute; margin-left:31.1pt;margin-top:0;width:66.75pt;height:73.5pt; z-index:251660288;mso-wrap-distance-left:0; mso-wrap-distance-top:0;mso-wrap-distance-right:0; mso-wrap-distance-bottom:0;mso-position-horizontal:right; mso-position-horizontal-relative:text; mso-position-vertical-relative:line' o:allowoverlap="f"> <v:imagedata src="http://staticapp.icpsc.com/icp/loadimage.php/mogile/815859/aa328bced6d9dbe22566d744af62c47a/image/jpeg"/> <w:wrap type="square"/> </v:shape><![endif]--><![if !vml]><img width=89 height=98 src="http://cancer.med.unc.edu/lcccnewsletter/wang.jpg" align=right v:shapes="_x0000_s1028"><![endif]><span style='font-size:8.5pt;font-family:"Trebuchet MS","sans-serif"; color:black'>Andrew Wang, MD, assistant professor of radiation oncology, has been awarded a $50,000 one-year grant from the Lung Cancer Research Foundation. <o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>The grant will fund research into the use of nanoparticles for drug delivery of DNA double-strand break repair inhibitors (DSBRIs) in combined chemotherapy and radiation therapy treatment of non-small cell lung cancer. DSBRIs can sensitize cancer cells to both chemotherapy and radiation therapy, but need to be delivered selectively to cancer cells, while sparing normal cells. Dr. Wang s lab will test nanoparticle formulations of DSBRIs and evaluate their effectiveness in laboratory models.<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> </div> </td> </tr> </table> </div> <p class=MsoNormal><span style='mso-fareast-font-family:"Times New Roman"'><o:p></o:p></span></p> </td> </tr> </table> </td> </tr> </table> </td> </tr> <tr style='mso-yfti-irow:2'> <td style='background:#DDEAF2;padding:0in 0in 0in 0in;border:transparent'> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;mso-cellspacing:0in;mso-yfti-tbllook: 1184;mso-padding-alt:0in 0in 0in 0in;word-wrap:break-word'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes'> <td valign=top style='padding:7.5pt 7.5pt 7.5pt 7.5pt;word-wrap:break-word'> <div> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;mso-cellspacing:0in;mso-yfti-tbllook: 1184;mso-padding-alt:0in 0in 0in 0in'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow: yes'> <td style='padding:0in 0in 0in 0in'> <p style='margin:0in;margin-bottom:.0001pt'><strong><span style='font-size:10.0pt;font-family:"Verdana","sans-serif"; color:black'>More Information</span></strong><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'><o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>For more information about Thoracic Oncology clinical trials, call: 919-966-4432.<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>To refer a patient to UNC Lineberger's Thoracic Oncology program, call 919-966-8128.<o:p></o:p></span></p> </td> </tr> </table> </div> </td> </tr> </table> </td> </tr> <tr style='mso-yfti-irow:3;mso-yfti-lastrow:yes'> <td style='border:solid #569FD3 4.5pt;padding:0in 0in 0in 0in'> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;mso-cellspacing:0in;mso-yfti-tbllook: 1184;mso-padding-alt:0in 0in 0in 0in;word-wrap:break-word'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow:yes'> <td valign=top style='padding:7.5pt 7.5pt 7.5pt 7.5pt'> <div> <table class=MsoNormalTable border=0 cellspacing=0 cellpadding=0 width="100%" style='width:100.0%;mso-cellspacing:0in;mso-yfti-tbllook: 1184;mso-padding-alt:0in 0in 0in 0in'> <tr style='mso-yfti-irow:0;mso-yfti-firstrow:yes;mso-yfti-lastrow: yes'> <td style='padding:0in 0in 0in 0in'> <p align=center style='margin:0in;margin-bottom:.0001pt;text-align: center'><span style='font-size:8.5pt;font-family:"Trebuchet MS","sans-serif"; color:black'><a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Funclineberger.org%2F">UNC Lineberger</a><a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Funclineberger.org%2F">&nbsp;</a>&nbsp;&nbsp; <a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Funclineberger.org%2Fnccancerhospital">N.C. Cancer Hospital</a><a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Funclineberger.org%2Fnccancerhospital">&nbsp;</a>&nbsp;&nbsp; <a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;m!%20sgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Funclineberger.org%2Fpatientcare%2Fclinical-trials">Clinical Trials </a>&nbsp;&nbsp;&nbsp; <a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Funclineberger.org%2Fpatientcare">Clinical Programs</a>&nbsp;&nbsp;&nbsp; <a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Funclineberger.org%2Fccsp%2Fabout">Comprehensive Cancer Support</a><o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>For questions about all clinical trials at UNC (including those at UNC that are also offered at other sites), contact the UNC Lineberger protocol office at 919-966-4432 or (toll-free) 1-877-668-0683.<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>&nbsp;<o:p></o:p></span></p> <p style='margin:0in;margin-bottom:.0001pt'><span style='font-size: 8.5pt;font-family:"Trebuchet MS","sans-serif";color:black'>To make an appointment at the N.C. Cancer Hospital for one of your patients, <a href="http://click.icptrack.com/icp/relay.php?r=23863711&amp;msgid=278008&amp;act=7WK0&amp;c=815859&amp;destination=http%3A%2F%2Funclineberger.org%2Freferring">visit our web page for referring physicians</a>. You may also contact the Carolina Consultation Center at 1-800-862-6264.<o:p></o:p></span></p> </td> </tr> </table> </div> </td> </tr> </table> </td> </tr> </table> </td> </tr> </table> </div> </td> </tr> </table> <p class=MsoNormal style='margin-bottom:12.0pt'><o:p>&nbsp;</o:p></p> </div> </body> </html>